NEO 214 Shows Enhanced Efficacy In Slowing Multiple Myeloma Cancer In Vitro

Induction of Pro-Apoptotic Endoplasmic ReticulumStress in Multiple Myeloma Cells by NEO214, PerillylAlcohol Conjugated to Rolipram

Authors: Thomas C. Chen, MD, PhD¹, Nymph Chan¹, Shirin Labib², Jiali Yu¹, Hee-Yeon Cho¹, Florence M. Hofman³, and Axel H. Schönthal²

A study conducted by NeOnc Technologies demonstrated that it NEO 214 formulation had a significant increase in the ability to target and kill cancer cells related to Multiple Myeloma, an incurable cancer of the blood affecting the proliferation of aberrant plasma cell growth.

The study showed that NEO 214, a conjugate of Rolipram with NeOnc’s highly refined Perillyl Alcohol, had effectiveness on an order of magnitude stronger than Rolipram used on its own. 

¹ Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA ² Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, ³ Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles,
CA 90089, US